Tokyo, Japan

Yositeru Ikeda

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Agc Inc.. Active years: 2021.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yositeru Ikeda: Innovator in Chemically Strengthened Glass

Introduction

Yositeru Ikeda is a prominent inventor based in Tokyo, Japan. He is known for his significant contributions to the field of glass production, particularly in the development of chemically strengthened glass. His innovative methods have paved the way for advancements in glass technology.

Latest Patents

Yositeru Ikeda holds 1 patent for his invention titled "Production method of chemically strengthened glass, and chemically strengthened glass." This patent outlines a method for producing chemically strengthened glass through a series of ion exchange steps involving specific inorganic salt compositions. The process enhances the durability and strength of the glass, making it suitable for various applications.

Career Highlights

Ikeda has made notable strides in his career, working with AGC Inc., a leading company in glass manufacturing. His expertise in glass technology has contributed to the company's reputation for innovation and quality in the industry.

Collaborations

Throughout his career, Yositeru Ikeda has collaborated with esteemed colleagues such as Izuru Kashima and Kaname Sekiya. These partnerships have fostered a creative environment that encourages the exchange of ideas and advancements in glass technology.

Conclusion

Yositeru Ikeda's work in the production of chemically strengthened glass exemplifies the spirit of innovation in the field of materials science. His contributions continue to influence the industry and inspire future advancements in glass technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…